Cas:99735-28-1 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane manufacturer & supplier

We serve Chemical Name:2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane CAS:99735-28-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane

Chemical Name:2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane
CAS.NO:99735-28-1
Synonyms:2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane
Molecular Formula:C16H24N2
Molecular Weight:244.37500
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:334.8ºC at 760 mmHg
Density:1.06g/cm3
Index of Refraction:1.581
PSA:6.48000
Exact Mass:244.19400
LogP:2.48010

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane Use and application,2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane technical grade,usp/ep/jp grade.


Related News: Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane manufacturer In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market. 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane supplier Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane vendor Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 2-Benzyl-7-ethyl-2,7-diazaspiro[4.4]nonane factory In 2004, the National Development and Reform Commission, the former Ministry of Health, and the Ministry of Finance jointly formulated and promulgated the Administrative Measures for the Configuration and Use of Large Medical Equipment. This method uses X-ray electronic computer tomography (CT) devices and medical magnetic resonance imaging equipment, digital subtraction angiography X-ray machines of 800 mA or more as the management products of large-scale medical equipment, Purchase and use need to be reported to the provincial health administrative department for approval before approval. However, in recent years, with the comprehensive coverage of medical insurance, such basic medical facilities are being widely popularized, and the relevant implementation rules have directly linked the number of equipment to the number of doctors. Therefore, as the demand for imaging equipment continues to increase, it will have a greater boosting effect on the upstream contrast agent and its raw material market.